Long-term efficacy of dobesilate in chronic patellar tendinopathy


Long-term efficacy of dobesilate in chronic patellar tendinopathy


Pedro Cuevas1, José Antonio Rodas2, Tomás Fernández Jaen3, Pedro Guillen3, Javier Angulo4, Guillermo Giménez-Gallego5

1Universidad Alfonso X el Sabio, Madrid, 2Mutualidad de Previsión Social de Futbolistas Españoles, Avilés, 3Fundacion Pedro Guillén, Clínica CEMTRO, Madrid, 4Servicio de Histología, Departamento de Investigación, Hospital Universitario Ramón y Cajal, Madrid, 5Departamento de Estructura y Función de Proteínas, Centro de Investigaciones Biológicas, Madrid, Spain.


International-Journal-of-Case-Reports-2d code

There is a wide variety of treatment options available for patellar tendinopathy, the majority of which are non-surgical, and no consensus exists on the optimal method of treatment. We report that peritendinous injection of dobesilate in patients with chronic patellar tendinopathy, resulted in significant long-term improvement in knee function and reduced pain.


Keywords: Patellar tendinopathy. Dobesilate. Peritendinous injection. Fibroblast growth factor


Free Full-text PDF


How to cite this article:
Pedro Cuevas, José Antonio Rodas, Tomás Fernández Jaen, Pedro Guillen, Javier Angulo Guillermo Giménez-Gallego.Long-term efficacy of dobesilate in chronic patellar tendinopathy. International Journal of Case Reports, 2018 2:27. DOI: 10.28933/ijcr-2018-05-2901.


References:

1. Bode G, Hammer T, Karvouniaris N, Feucht MJ, Konstantinidis L, Südkamp NP, Hirschmüller A. Patellar tendinopathy in young elite soccer- clinical and sonographical analysis of a german elite soccer academy. BMC Musculoskelet Disord. 2017;18:344. doi: 10.1186/s12891-017-1690-2.
2. Lian OB, Engebretsen L, Bahr R.Prevalence of jumper’s knee among elite athletes from different sports: a cross-sectional study. Am J Sports Med. 2005;33:561-7.
3. Cook JL, Khan KM. What is the most appropriate treatment for patellar tendinopathy? Br J Sports Med. 2001;35:291-4.
4. Perry SM, McIlhenny SE, Hoffman MC, Soslowsky LJ. Inflammatory and angiogenic mRNA levels are altered in a supraspinatus tendon overuse animal model. J Shoulder Elbow Surg. 2005;14 (1 Suppl S):79S-83S.
5. Petersen W1, Varoga D, Zantop T, Hassenpflug J, Mentlein R, Pufe T. Cyclic strain influences the expression of the vascular endothelial growth factor (VEGF) and the hypoxia inducible factor 1 alpha (HIF-1alpha) in tendon fibroblasts. J Orthop Res. 2004; 22: 847-53.
6. Sahin H, Tholema N, Petersen W, Raschke MJ, Stange R. Impaired biomechanical properties correlate with neoangiogenesis as well as VEGF and MMP-3 expression during rat patellar tendon healing. J Orthop Res. 2012;30: 1952-7. doi: 10.1002/jor.22147.
7. Cuevas P, Rodas JA, Angulo J, Giménez-Gallego G. Short-term. efficacy of etamsylate injection in chronic patellar tendinopathy. SM J Clin Med. 2017; 3: 1029.
8. Ohberg L, Lorentzon R, Alfredson H. Neovascularisation in Achilles tendons with painful tendinosis but not in normal tendons: an ultrasonographic investigation. Knee Surg Sports Traumatol Arthrosc. 2001;9:233-8.
9. Weinberg EP, Adams MJ, Hollenberg GM. Color Doppler sonography of patellar tendinosis. AJR Am J Roentgenol. 1998;171:743-4.
10. Robinson JM, Cook JL, Purdam C, Visentini PJ, Ross J, Maffulli N, Taunton JE, Khan KM; Victorian Institute Of Sport Tendon Study Group. The VISA-A questionnaire: a valid and reliable index of the clinical severity of Achilles tendinopathy. Br J Sports Med. 2001; 35:335-41.
11. Ooi CC, Schneider ME, Malliaras P, Jones D, Saunders S, McMahon A, Connell D.Sonoelastography of the Achilles tendon: prevalence and prognostic value among asymptomatic elite australian rules football players. Clin J Sport Med. 2016; 26:299-306. doi: 10.1097/JSM.265.
12. Alfredson H, Ohberg L, Forsgren S. Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections. Knee Surg Sports Traumatol Arthrosc. 2003 ; 11:334-8.
13. Zanetti M, Metzdorf A, Kundert HP, Zollinger H, Vienne P, Seifert B, Hodler J. Achilles tendons: clinical relevance of neovascularization diagnosed with power Doppler US. Radiology. 2003; 227:556-60.
14. Rees JD, Wilson AM, Wolman RL.Current concepts in the management of tendon disorders. Rheumatology (Oxford). 2006 ; 45:508-21.
15. Scott A, Danielson P. An Emerging Role for Angiogenesis in Tendinopathy. Eur Musculoskelet Rev. 2009; 4:75-76.
16. Thomas KA, Rios-Candelore M, Giménez-Gallego G, DiSalvo J, Bennett C, Rodkey J, Fitzpatrick S. Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1. Proc Natl Acad Sci U S A. 1985; 82:6409-13.
17. Mousavizadeh R, Khosravi S, Behzad H, McCormack RG, Duronio V, Scott A. Cyclic strain alters the expression and release of angiogenic factors by human tendon cells. PLoS One. 2014; 9:e97356. doi: 10.1371
18. Salles JI, Amaral MV, Aguiar DP, Lira DA, Quinelato V, Bonato LL, Duarte ME, Vieira AR, Casado PL. BMP4 and FGF3 haplotypes increase the risk of tendinopathy in volleyball athletes. J Sci Med Sport. 2015; 18:150-5. doi: 10.1016/j.jsams.2014.02.011
19. Fernández IS, Cuevas P, Angulo J, López-Navajas P, Canales-Mayordomo A, González-Corrochano R, Lozano RM, Valverde S, Jiménez-Barbero J, Romero A, Giménez-Gallego G. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem. 2010; 285: 11714-29. doi: 10.1074/jbc.M109.064618.
20. Angulo J, Cuevas P, Cuevas B, El Youssef M, Fernández A, Martínez-Salamanca E, González-Corrochano R, Giménez-Gallego G. Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities. J Transl Med. 2015; 13:48. doi: 10.1186/s12967-015-0413-4.
21. Oladipupo SS, Smith C, Santeford A, Park C, Sene A, Wiley LA, Osei-Owusu P, Hsu J, Zapata N, Liu F, Nakamura R, Lavine KJ, Blumer KJ, Choi K, Apte RS, Ornitz DM. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci U S A. 2014; 111:13379-84. doi: 10.1073/pnas.1324235111.
22. Andres C, Hasenauer J, Ahn HS, Joseph EK, Isensee J, Theis FJ, Allgöwer F, Levine JD, Dib-Hajj SD, Waxman SG, Hucho T.Wound-healing growth factor, basic FGF, induces Erk1/2-dependent mechanical hyperalgesia. Pain. 2013; 154:2216-26. doi: 10.1016/j.pain.2013.07.005
23. Liu H, Wu QE, Li JY, Liu XJ, Li KC, Zhong YQ, Wu D, Wang Q, Lu YJ, Bao L, Zhang X. Fibroblast growth factor 7 is a nociceptive modulator secreted via large dense-core vesicles. J Mol Cell Biol. 2015; 7:466-75. doi: 10.1093/jmcb/mjv019.
24. Madiai F, Goettl VM, Hussain SR, Clairmont AR, Stephens RL Jr, Hackshaw KV. Anti-fibroblast growth factor-2 antibodies attenuate mechanical allodynia in a rat model of neuropathic pain. J Mol Neurosci. 2005;27:315-24.
25. Im HJ, Li X, Muddasani P, Kim GH, Davis F, Rangan J, Forsyth CB, Ellman M, Thonar EJ. Basic fibroblast growth factor accelerates matrix degradation via a neuro-endocrine pathway in human adult articular chondrocytes. J Cell Physiol. 2008;215:452-63.
26. Gotoh M, Hamada K, Yamakawa H, Inoue A, Fukuda H. Increased substance P in subacromial bursa and shoulder pain in rotator cuff diseases. J Orthop Res. 1998; 16:618-21.
27. Andersson G, Backman LJ, Scott A, Lorentzon R, Forsgren S, Danielson P. Substance P accelerates hypercellularity and angiogenesis in tendon tissue and enhances paratendinitis in response to Achilles tendon overuse in a tendinopathy model. Br J Sports Med. 2011; 45:1017-22. doi: 10.1136/bjsm.2010.082750